Last updated: September 2, 2026
Cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution is a mature prescription mydriatic and cycloplegic combination used to dilate the pupil and temporarily paralyze accommodation during eye examinations. The principal branded product is Cyclomydril, historically marketed by Alcon Laboratories. Its commercial profile is defined by low clinical differentiation, long-established active ingredients, generic substitution, limited patent protection, and demand tied to ophthalmology and pediatric eye-care volumes rather than pharmaceutical innovation.
Product-level revenue is not separately disclosed by Alcon. The financial trajectory is therefore best assessed through market structure, prescription demand, competitive substitutes, regulatory status, supply economics, and the absence of meaningful remaining exclusivity.
What is cyclopentolate hydrochloride and phenylephrine hydrochloride used for?
The fixed-dose ophthalmic combination is used for diagnostic pupil dilation and cycloplegia. Cyclopentolate blocks muscarinic receptors in the iris sphincter and ciliary muscle. Phenylephrine stimulates alpha-adrenergic receptors to produce mydriasis.
Cyclomydril contains:
| Component |
Concentration |
Primary function |
| Cyclopentolate hydrochloride |
0.2% |
Cycloplegia and mydriasis |
| Phenylephrine hydrochloride |
1.0% |
Mydriasis |
The product is administered topically before ophthalmic examination. Its main use cases include pediatric refraction, retinal examination, and diagnostic procedures requiring pupil dilation. The FDA label identifies contraindications and precautions relating to narrow-angle glaucoma, cardiovascular effects, systemic absorption, and pediatric use.[1]
The combination is clinically useful because the two ingredients produce complementary effects. Cyclopentolate provides cycloplegia, while phenylephrine strengthens pupil dilation. The product competes with separate-agent administration, tropicamide-based products, phenylephrine monotherapy, and stronger cycloplegic regimens such as atropine.
What is the FDA regulatory status of Cyclomydril?
Cyclomydril is an FDA-approved prescription ophthalmic solution associated with New Drug Application 018699. The product is a conventional small-molecule ophthalmic drug rather than a biologic, device-drug combination, or complex injectable.[1]
The regulatory characteristics are commercially important:
- The active ingredients have been used in ophthalmology for decades.
- The product does not depend on a novel molecular mechanism.
- FDA approval is based on established pharmacology and ophthalmic safety data.
- The main regulatory barriers concern sterile manufacturing, preservative control, container-closure integrity, labeling, and quality testing.
- The product does not have biosimilar exposure because it is not a biologic.
The fixed combination is subject to the standard prescription-drug framework. Generic applicants can pursue approval under the abbreviated new drug application pathway when they establish pharmaceutical equivalence, bioequivalence where applicable, and comparable quality performance.
What is the Orange Book status of cyclopentolate and phenylephrine ophthalmic solution?
The commercial opportunity is not protected by a meaningful period of new-drug exclusivity. Cyclopentolate and phenylephrine are old active pharmaceutical ingredients, and the fixed combination has been marketed for many years.
The relevant Orange Book analysis has four elements:
| Issue |
Assessment |
| Reference product |
Cyclomydril, associated with NDA 018699 |
| New chemical entity exclusivity |
Not applicable to these long-established ingredients |
| Pediatric exclusivity |
No current product-level pediatric exclusivity is expected to block entry |
| Patent-based exclusivity |
No commercially significant active composition or formulation patent barrier is evident from the mature product history |
Orange Book status can change through labeling updates, discontinuation coding, or changes in listed patent information. The economic conclusion remains stable: the combination is a mature product with limited patent-based pricing power.[2]
When does cyclopentolate and phenylephrine lose exclusivity?
The product’s meaningful market exclusivity expired long ago. Cyclopentolate and phenylephrine are not recent launch molecules, and Cyclomydril is well beyond the period in which regulatory exclusivity would support premium pricing.
The practical loss-of-exclusivity timeline is:
| Period |
Commercial condition |
| Original launch period |
Branded fixed-dose combination marketed with limited direct competition |
| Generic entry period |
Sterile ophthalmic competitors and separate-agent alternatives reduce pricing power |
| Current market |
Mature, procurement-driven market with limited product differentiation |
There is no credible basis for projecting a new exclusivity event for the existing formulation. Any future commercial protection would need to come from a reformulation, delivery technology, preservative-free presentation, packaging improvement, or a new clinical indication.
What patents protect cyclopentolate hydrochloride and phenylephrine hydrochloride?
The core active ingredients are not protected by commercially relevant composition-of-matter patents. Any original patents associated with cyclopentolate, phenylephrine, or early ophthalmic formulations expired many years ago.
Potential patent categories include:
- Active-ingredient patents. These are expired for the established molecules.
- Fixed-dose combination patents. No material active patent barrier is apparent for the conventional Cyclomydril formulation.
- Formulation patents. Sterility, pH, tonicity, preservative systems, and excipient combinations can theoretically support patents, but routine formulation claims are difficult to sustain as a durable barrier for an old ophthalmic product.
- Container-closure patents. Packaging patents may protect a specific bottle, dropper, or unit-dose format, but they generally do not block the active drug combination.
- Method-of-use patents. No commercially important current method-of-use patent is associated with standard diagnostic dilation and cycloplegia.
The principal protection today is manufacturing know-how and regulatory execution, not patent exclusivity.
How strong is the patent estate for Cyclomydril?
The patent estate is weak from a commercial exclusivity perspective.
A practical scoring framework is:
| Patent factor |
Assessment |
| Composition-of-matter protection |
None expected |
| Fixed-combination protection |
Weak or expired |
| Formulation protection |
Potentially narrow and design-aroundable |
| Method-of-use protection |
Minimal |
| Manufacturing protection |
Moderate operational value, limited legal exclusion |
| Patent litigation leverage |
Low |
| Ability to sustain premium pricing |
Low |
Sterile ophthalmic production can create operational barriers without creating a durable patent moat. A competitor may need validated aseptic processes, compliant facilities, stability data, and reliable supply. Those requirements increase execution cost but do not prevent entry by an established ophthalmic manufacturer.
Which companies compete with cyclopentolate and phenylephrine ophthalmic products?
Competition comes from both fixed-dose products and therapeutic substitutes.
Fixed-dose and same-class competition
The closest competitors are generic versions of cyclopentolate and phenylephrine ophthalmic solution, where available, plus products supplied through hospital, clinic, and specialty-pharmacy channels.
Separate-agent substitution
Clinicians may administer cyclopentolate and phenylephrine separately. This approach provides dosing flexibility and can be preferable when the physician wants to adjust cycloplegia or mydriasis independently.
Therapeutic alternatives
Key alternatives include:
- Tropicamide ophthalmic products for routine dilation.
- Phenylephrine ophthalmic products used separately.
- Cyclopentolate monotherapy for cycloplegic refraction.
- Atropine for stronger or longer-duration cycloplegia, particularly in selected pediatric cases.
- Homatropine or other anticholinergic agents in specialized settings.
The combination has a narrower competitive position than a product with a unique indication. Its demand depends on workflow convenience, clinician preference, pediatric utility, availability, and acquisition price.
What is the market demand for cyclopentolate and phenylephrine?
Demand is relatively stable but low growth. The primary volume drivers are:
- Number of ophthalmology examinations.
- Pediatric vision screening and refractive assessments.
- Retinal and anterior-segment diagnostic procedures.
- Availability of eye-care professionals.
- Hospital and ambulatory clinic procedure volumes.
- Generic supply reliability.
- Prescribing practices in children and adolescents.
The market is less exposed to chronic medication adherence than glaucoma or retinal disease products. A dose is used episodically during an examination, so revenue correlates more closely with procedure volume than with the number of diagnosed patients.
Demand is also vulnerable to substitution. A clinic may use tropicamide for routine adult dilation or separate cyclopentolate and phenylephrine when cost or dosing flexibility favors that approach.
What is the financial trajectory of cyclopentolate and phenylephrine?
The financial trajectory is mature to declining in branded terms, with stable low-value demand in the broader ophthalmic market.
| Financial driver |
Expected effect |
| Generic competition |
Sustained price compression |
| No meaningful exclusivity |
Prevents premium pricing |
| Stable eye-exam volumes |
Supports baseline unit demand |
| Pediatric cycloplegia |
Preserves specialized use |
| Product shortages |
Can temporarily improve pricing or shift share |
| Sterile manufacturing costs |
Limits margin at low price points |
| Alcon portfolio disclosure |
Prevents separate product-level revenue analysis |
Alcon reports revenue at business-segment and portfolio levels rather than disclosing Cyclomydril sales as a standalone product. The product therefore cannot be valued using a reported brand revenue series. Its economic contribution is more likely to be measured through portfolio retention, channel presence, and incremental ophthalmic sales than through material standalone revenue.
For a generic manufacturer, the opportunity is a recurring but modest-volume sterile ophthalmic product. Gross margins depend on manufacturing scale, procurement contracts, preservative and packaging costs, product availability, and the number of approved competitors.
For the branded manufacturer, the strategic value is limited unless the product is bundled with a broader ophthalmic portfolio. A standalone relaunch would face low switching costs and immediate price competition.
What generic entry risks exist for Cyclomydril?
Generic entry risk is high because the product has several characteristics that favor substitution:
- Long-established active ingredients.
- Conventional ophthalmic dosage form.
- No apparent active patent barrier.
- Established clinical use.
- Straightforward labeling framework.
- Multiple therapeutic alternatives.
- Procurement channels that emphasize price and supply continuity.
The main obstacles are technical rather than legal. A generic applicant must manufacture a sterile ophthalmic product that meets specifications for potency, impurities, particulate matter, sterility, preservative effectiveness, pH, osmolality, and container performance.
These requirements can delay approval or create supply problems, but they do not provide the reference product with long-term legal exclusivity.
Which companies are challenging Cyclomydril through Paragraph IV filings?
No major publicly reported Paragraph IV litigation is associated with the fixed-dose cyclopentolate hydrochloride and phenylephrine hydrochloride product in the available public record through 2024.
The absence of prominent litigation is consistent with the product’s age and low expected value of patent enforcement. If a generic applicant were to file a Paragraph IV certification against an active listed patent, the reference sponsor would have a potential 45-day period to initiate litigation under the Hatch-Waxman framework. That scenario does not appear to be the central competitive issue for this product.[3]
The more likely pathway is ordinary generic competition after any listed patents are expired, disclaimed, delisted, or otherwise incapable of supporting a meaningful injunction.
What manufacturing and intellectual-property barriers affect the market?
The strongest barriers are operational:
Sterile ophthalmic manufacturing
Manufacturers need validated aseptic production, sterile filtration or other approved sterilization controls, cleanroom capacity, environmental monitoring, and reliable fill-finish operations.
Supply-chain concentration
A limited number of facilities may produce particular ophthalmic presentations. A manufacturing interruption can cause short-term shortages, even when the underlying drug has no patent protection.
Packaging and preservative systems
Multidose bottles require container-closure performance and preservative control. Unit-dose presentations can reduce preservative exposure but may increase packaging and per-dose costs.
Quality-system compliance
FDA observations, warning letters, import restrictions, or remediation programs can affect supply more quickly than patent disputes. For mature ophthalmic products, regulatory manufacturing performance often determines market share.
These barriers support dependable suppliers but do not create the pricing power associated with patented products.
How does this product compare with tropicamide and atropine?
| Attribute |
Cyclopentolate plus phenylephrine |
Tropicamide |
Atropine |
| Main role |
Mydriasis plus cycloplegia |
Rapid routine dilation |
Strong, prolonged cycloplegia |
| Typical setting |
Pediatric and diagnostic examinations |
Routine adult examinations |
Selected pediatric or specialized use |
| Duration |
Intermediate |
Shorter |
Longest |
| Convenience |
Fixed combination |
Single active ingredient |
Stronger effect with more prolonged recovery |
| Commercial maturity |
Mature generic market |
Mature generic market |
Mature generic market |
| Price power |
Low |
Low |
Low to moderate in specialized use |
The combination retains relevance where clinicians want a stronger diagnostic regimen than tropicamide alone. It loses share when rapid recovery, low cost, or simpler routine dilation is the priority.
What litigation and settlement agreements affect the product?
No major patent litigation or settlement agreement appears to materially affect the current commercial position of cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution.
The market is therefore shaped by:
- FDA approval and manufacturing compliance.
- Generic application timing.
- Drug-shortage conditions.
- Wholesaler and institutional purchasing.
- Clinical substitution.
- Product availability.
This differs from high-value branded drugs, where patent settlements can determine the date of generic launch and preserve substantial revenue.
What is the geographic coverage of the market?
The product is most commercially relevant in the United States and other markets with established ophthalmology infrastructure. Geographic performance depends on:
- National approval of the fixed combination.
- Availability of sterile ophthalmic manufacturing.
- Pediatric eye-care capacity.
- Reimbursement and procurement practices.
- Use of local alternatives.
- Distribution through hospitals, clinics, and pharmacies.
The U.S. market has the clearest regulatory framework and the most visible generic-substitution economics. International markets may use different concentrations, separate active ingredients, or locally preferred mydriatic combinations.
What generic launch scenarios are most likely?
Three scenarios define the market:
Continued mature competition
This is the base case. Generic and branded suppliers compete on price, quality, and availability. Market growth tracks examination volumes and remains modest.
Supply disruption and temporary share transfer
A shortage at one manufacturer can shift prescriptions to another supplier. This may temporarily improve volume and pricing for available products, but it does not create durable exclusivity.
Reformulated or preservative-free entry
A manufacturer could seek differentiation through unit-dose packaging, preservative-free delivery, improved pediatric usability, or a redesigned container. Such products may support better pricing, but they would compete against the regulatory and manufacturing cost of developing a differentiated presentation.
Key Takeaways
- Cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution is a mature diagnostic ophthalmic combination.
- Cyclomydril is the principal historical branded product and is associated with NDA 018699.
- The active ingredients and conventional fixed-dose formulation have no meaningful remaining composition-of-matter exclusivity.
- Patent strength is low; manufacturing quality and supply reliability are more important than intellectual property.
- Generic entry risk is high, while major Paragraph IV litigation and settlement activity are not publicly prominent.
- Demand is linked to ophthalmology examination volumes, pediatric cycloplegic refraction, and diagnostic workflows.
- Product-level revenue is not separately disclosed by Alcon, preventing a standalone financial series.
- The branded financial trajectory is mature and price constrained. Generic suppliers can earn recurring revenue, but the opportunity is unlikely to support high pharmaceutical margins without differentiated packaging or supply advantages.
- Biosimilar risk is not relevant because the product contains small-molecule active ingredients.
- The main commercial risks are substitution, low pricing, sterile manufacturing failures, and product shortages.
FAQs
Is cyclopentolate and phenylephrine ophthalmic solution still commercially relevant?
Yes. It remains relevant for diagnostic dilation and cycloplegic refraction, particularly in pediatric and specialty ophthalmology, although routine adult dilation often uses tropicamide or other alternatives.
Can a company obtain new patents on a cyclopentolate-phenylephrine eye drop?
A company could pursue patents on a novel formulation, preservative-free presentation, container, dosing system, or manufacturing process. Those rights would not automatically extend to the underlying active ingredients or conventional combination.
Does Cyclomydril have biosimilar competition?
No. Biosimilar rules apply to biologic products. Cyclomydril contains conventional small-molecule drugs and is exposed to generic-drug competition instead.
Why can an old ophthalmic drug remain profitable after patent expiration?
Profit can persist through recurring procedure demand, established distribution, manufacturing scale, limited supplier competition, and temporary shortages. The margin profile is usually lower than for a patented branded drug.
What is the biggest investment risk in this market?
The largest risk is limited pricing power. Even where demand is stable, generic substitution, low per-dose pricing, alternative mydriatics, and sterile manufacturing costs can restrict revenue growth and margins.
References
-
U.S. Food and Drug Administration. (n.d.). Cyclomydril prescribing information: Cyclopentolate hydrochloride and phenylephrine hydrochloride ophthalmic solution. Alcon Laboratories, Inc.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
U.S. Food and Drug Administration. (2024). Paragraph IV drug product applications: Patent certifications and litigation framework. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda/paragraph-iv-drug-product-applications
